Hyloris Pharmaceuticals Reports 2022 Half-Year Results and

01.09.2022 - - On track to broaden product pipeline to meet a target portfolio of 30 programs by 2024- Continued commercial rollout of Sotalol IV in US and Maxigesic IV - Focused entry into US market with Maxigesic IV for non-opioid pain treatment; continuing ...

Related Keywords

Belgium , Norway , Japan , United States , China , Portugal , Indonesia , Kosovo , Canada , Woman , Bahrain , Mexico , Netherlands , Singapore , Italy , Finland , Greece , Vulvovaginal Candidiasis , Van Rompay , Stijn Van Rompay , Alter Pharma Group , Hyloris Pharmaceuticals Sa Euronext Brussels , Hyloris Pharmaceuticals , Drug Administration , Tranexamic Acid Oral Mouth , Euronext Brussels , Chief Executive Officer , United States Food , Complete Response Letter , Developments Related , Acid Oral Mouth Rinse , Recurrent Vulvovaginal Candidiasis , Financial Highlights , Capital Transactions , Full Year , Business Update ,